Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
ACTR087 is a chimeric construct consisting of the extracellular domain of CD16 linked to CD3zeta signaling and 41BB co-stimulatory domains delivered into human T-cells via gamma-retrovirus, which may lead to enhanced anti-tumor activity in combination with tumor-targeting antibodies (Blood 2016, 128(22):3512).
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|ACTR087 + Rituximab||ACTR087 Rituximab||0||1|
|ACTR087 + SEA-BCMA||ACTR087 SEA-BCMA||0||1|
|ACTR087 + Trastuzumab||ACTR087 Trastuzumab||0||1|